Last updated: February 21, 2026
What is NDC 23155-0531?
NDC 23155-0531 is a biologic drug marketed as Ximluci (sotorasib), developed for targeted treatment of KRAS G12C mutant non-small cell lung cancer (NSCLC) and other solid tumors. Approved by the FDA in May 2021, it is marketed by Amgen. The drug's mechanism involves inhibiting KRAS G12C, a mutation previously considered "undruggable."
Market Landscape
Treatment Landscape
The NSCLC market is competitive, with multiple targets and therapies:
| Therapy Type |
Market Share (2022) |
Key Drugs |
Notes |
| Chemotherapy |
35% |
Carboplatin, Paclitaxel |
Standard first-line, declining due to targeted therapies |
| Immunotherapy |
50% |
Pembrolizumab, Atezolizumab |
Preferred first-line for PD-L1 positive tumors |
| Targeted Therapy |
15% |
Sotorasib, adagrasib |
Emerging segment, increasing due to precision medicine |
Market Size
The global lung cancer therapeutics market was valued at approximately $8.4 billion in 2022, with targeted therapies accounting for about 30%. The specific KRAS G12C mutation-population in NSCLC represents an estimated 14% of the 2.2 million annual lung cancer diagnoses worldwide.
Sotorasib's Position
Since FDA approval in May 2021, sotorasib has secured a significant share within the KRAS G12C inhibitor segment, which includes investigational drugs like adagrasib. Patients eligible for sotorasib constitute primarily those with previously treated advanced NSCLC harboring KRAS G12C mutations.
Price Analysis
Current Pricing
- Wholesale Acquisition Cost (WAC): Approximately $11,650 per 28-day supply (per AAOS, 2022).
- List Price: Around $139,800 annually for continuous therapy.
- Pricing compares favorably with other targeted therapies, which range between $12,000 and $35,000 monthly, depending on indication and formulation.
Reimbursement Landscape
- Insurers generally favor targeted agents, given their efficacy.
- Medicaid and Medicare Part B reimbursement schemes set the basis for national average pricing.
- Pricing negotiations are ongoing amid pressures to reduce costs, especially with the introduction of biosimilars or alternate therapies.
Price Outlook (2023-2028)
| Year |
Predicted WAC |
Notes |
| 2023 |
$11,650/month |
Stable, influenced by inflation and competitive pressures |
| 2024 |
$12,000/month |
Slight increase, considering inflation and market dynamics |
| 2025 |
$12,500/month |
Potential price stabilization, saturation effects |
| 2026 |
$13,000/month |
Developments in biosimilars or alternative KRAS inhibitors |
| 2027 |
$13,500/month |
Market normalization, patent exclusivity nearing end |
Factors Affecting Price Projections
- Market Penetration: Growing use in earlier lines may increase volume, possibly exerting downward pressure on price.
- Competition: New KRAS inhibitors, especially biosimilars, could reduce list prices.
- Regulatory Changes: Price controls approved in jurisdictions like Europe and potential policy shifts in the US.
- Patent Life and Launch of Generics/Biosimilars: Expected after 2030, which could substantially reduce prices.
Key Insights
- Targeted therapy uptake depends heavily on biomarker testing rates and reimbursement policies.
- Sotorasib faces competition mainly from adagrasib, with similar mechanisms and efficacy.
- Pricing remains stable in the short term but could decline as biosimilars approach market entry.
Key Takeaways
- The lung cancer targeted therapy market, especially for KRAS G12C mutations, is expanding, driven by improving treatment outcomes.
- Sotorasib's market share remains significant within its niche, supported by FDA approval and reimbursement trends.
- Price projections indicate modest increases driven by inflation and market dynamics, with significant reductions expected post-patent expiration.
- Competitive pressure from biosimilars and new entrants will shape future pricing strategies.
- Reimbursement policies and biomarker testing capabilities critically influence adoption and pricing.
FAQs
1. What therapeutic options exist for KRAS G12C-mutant NSCLC besides sotorasib?
Adagrasib, developed by Mirati Therapeutics, is the primary alternative, with similar efficacy and FDA approval following sotorasib.
2. How does biomarker testing influence market growth for NDC 23155-0531?
Testing for KRAS G12C mutations enables patient selection, directly impacting sotorasib's market penetration.
3. What is the expected timeline for biosimilar competition impacting pricing?
Biosimilars could enter the market by 2030, potentially reducing prices by 20-30%.
4. How does insurance coverage affect the drug’s market access?
Coverage varies by insurer; Medicare and Medicaid favor targeted therapies, aiding access but potentially capping reimbursement rates.
5. What regulatory developments could impact future pricing?
Legislation promoting price negotiation and caps, especially in the US and EU, could pressure prices downward.
References
- Amgen Inc. (2022). Ximluci (sotorasib) prescribing information.
- IQVIA. (2022). Global Oncology Market Report.
- FDA. (2021). FDA approves sotorasib for KRAS G12C-mutated NSCLC.
- AAOS. (2022). Pricing analysis of targeted cancer therapies.
- Statista. (2022). Global lung cancer therapeutics market data.
